Matches in SemOpenAlex for { <https://semopenalex.org/work/W2414258587> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2414258587 abstract "Vascular endothelial growth factor (VEGF-A) is a major regulator of angiogenesis and vascular permeability. VEGF-A plays an important role in a wide variety of retinal diseases. Therefore, intravitreal injection of anti-VEGF agents is increasingly used for the treatment of various vasoproliferative or exudative retinal diseases. There are several antiVEGF drugs available that are currently used, but three are most commonly used in practice. They are ranibizumab, bevacizumab, and aflibercept. Ranibizumab is a humanized monoclonal antibody fragment targeting VEGF-A, but bevacizumab, commonly used off-label, is a humanized full-length anti-VEGF antibody. Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1. These anti-VEGF therapies have resulted in unprecedented visual and anatomic outcomes, especially in patients with neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME). Visual stabilization or clinically significant visual improvement can be expected if intravitreal injections of anti-VEGF agents are properly provided for patients with neovascular AMD or DME in the course of the disease. Treating retinal diseases with intravitreal injection of anti-VEGF agents may have potential side effects. Systemic adverse effects attributable to VEGF inhibition may cause thromboembolic events. Acute endophthalmitis is the most feared injection-related ocular side effect. The development of anti-VEGF agents for various retinal diseases provides a safe and effective treatment. There is no doubt that further advances in anti-VEGF therapy can be expected soon." @default.
- W2414258587 created "2016-06-24" @default.
- W2414258587 creator A5010448477 @default.
- W2414258587 date "2016-01-01" @default.
- W2414258587 modified "2023-09-25" @default.
- W2414258587 title "Intravitreal injection of anti-vascular endothelial growth factor for patients with various retinal diseases" @default.
- W2414258587 cites W1481978003 @default.
- W2414258587 cites W1786299986 @default.
- W2414258587 cites W2004117352 @default.
- W2414258587 cites W2022886290 @default.
- W2414258587 cites W2124415048 @default.
- W2414258587 cites W2146673937 @default.
- W2414258587 doi "https://doi.org/10.5124/jkma.2016.59.1.52" @default.
- W2414258587 hasPublicationYear "2016" @default.
- W2414258587 type Work @default.
- W2414258587 sameAs 2414258587 @default.
- W2414258587 citedByCount "0" @default.
- W2414258587 crossrefType "journal-article" @default.
- W2414258587 hasAuthorship W2414258587A5010448477 @default.
- W2414258587 hasBestOaLocation W24142585871 @default.
- W2414258587 hasConcept C113045295 @default.
- W2414258587 hasConcept C118487528 @default.
- W2414258587 hasConcept C141071460 @default.
- W2414258587 hasConcept C142724271 @default.
- W2414258587 hasConcept C167734588 @default.
- W2414258587 hasConcept C2776403814 @default.
- W2414258587 hasConcept C2776694085 @default.
- W2414258587 hasConcept C2777025900 @default.
- W2414258587 hasConcept C2777512022 @default.
- W2414258587 hasConcept C2777802072 @default.
- W2414258587 hasConcept C2778749236 @default.
- W2414258587 hasConcept C2779742858 @default.
- W2414258587 hasConcept C2780827179 @default.
- W2414258587 hasConcept C2781100027 @default.
- W2414258587 hasConcept C502942594 @default.
- W2414258587 hasConcept C71924100 @default.
- W2414258587 hasConcept C98274493 @default.
- W2414258587 hasConceptScore W2414258587C113045295 @default.
- W2414258587 hasConceptScore W2414258587C118487528 @default.
- W2414258587 hasConceptScore W2414258587C141071460 @default.
- W2414258587 hasConceptScore W2414258587C142724271 @default.
- W2414258587 hasConceptScore W2414258587C167734588 @default.
- W2414258587 hasConceptScore W2414258587C2776403814 @default.
- W2414258587 hasConceptScore W2414258587C2776694085 @default.
- W2414258587 hasConceptScore W2414258587C2777025900 @default.
- W2414258587 hasConceptScore W2414258587C2777512022 @default.
- W2414258587 hasConceptScore W2414258587C2777802072 @default.
- W2414258587 hasConceptScore W2414258587C2778749236 @default.
- W2414258587 hasConceptScore W2414258587C2779742858 @default.
- W2414258587 hasConceptScore W2414258587C2780827179 @default.
- W2414258587 hasConceptScore W2414258587C2781100027 @default.
- W2414258587 hasConceptScore W2414258587C502942594 @default.
- W2414258587 hasConceptScore W2414258587C71924100 @default.
- W2414258587 hasConceptScore W2414258587C98274493 @default.
- W2414258587 hasLocation W24142585871 @default.
- W2414258587 hasOpenAccess W2414258587 @default.
- W2414258587 hasPrimaryLocation W24142585871 @default.
- W2414258587 hasRelatedWork W1529643435 @default.
- W2414258587 hasRelatedWork W1988252501 @default.
- W2414258587 hasRelatedWork W1991311930 @default.
- W2414258587 hasRelatedWork W2000650722 @default.
- W2414258587 hasRelatedWork W2029628510 @default.
- W2414258587 hasRelatedWork W2036279685 @default.
- W2414258587 hasRelatedWork W2048055194 @default.
- W2414258587 hasRelatedWork W2067380467 @default.
- W2414258587 hasRelatedWork W2209319212 @default.
- W2414258587 hasRelatedWork W2218436155 @default.
- W2414258587 hasRelatedWork W2768963146 @default.
- W2414258587 hasRelatedWork W2886924097 @default.
- W2414258587 hasRelatedWork W2995472573 @default.
- W2414258587 hasRelatedWork W2999264130 @default.
- W2414258587 hasRelatedWork W3010918112 @default.
- W2414258587 hasRelatedWork W3029628557 @default.
- W2414258587 hasRelatedWork W3135885187 @default.
- W2414258587 hasRelatedWork W42371127 @default.
- W2414258587 hasRelatedWork W62171837 @default.
- W2414258587 hasRelatedWork W2183760585 @default.
- W2414258587 isParatext "false" @default.
- W2414258587 isRetracted "false" @default.
- W2414258587 magId "2414258587" @default.
- W2414258587 workType "article" @default.